ArticleBreast cancer (Dove Medical Press)2025
Neuregulin-1 Secreted by Cancer-Associated Fibroblasts Promotes Growth of Triple-Negative Breast Cancer.
Article in Breast cancer (Dove Medical Press), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer lacking estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, which limits targeted therapies. Cancer-associated fibroblasts (CAFs) in the tumor microenvironment are known to secrete factors that promote tumor progression. The role of neuregulin-1 (NRG1), a ligand of HER3 and HER4, in TNBC and its association with CAFs remains unclear. Methods: We analyzed NRG1 mRNA and protein levels in TNBC tumor and adjacent tissues using qRT-PCR and ELISA, and evaluated their relationship with clinicopathological parameters and prognosis in 174 patients. Serum NRG1 levels were assessed via ELISA in TNBC patients and healthy controls. The effects of CAF-secreted NRG1 on TNBC cells were studied using conditioned medium, siRNA knockdown, and xenograft mouse models. Statistical analyses, including ROC curves and survival analyses, were performed to determine diagnostic and prognostic value. Results: NRG1 expression was significantly upregulated in TNBC tissues and serum compared to controls, correlating with advanced TNM stages and poor prognosis. ROC analysis demonstrated diagnostic value of NRG1 in tissues and serum. CAFs secreted higher levels of NRG1 compared to normal fibroblasts. Conditioned medium from CAFs enhanced TNBC cell proliferation, migration, and MMP9 expression, effects reduced by NRG1 knockdown. In vivo, CAF-conditioned medium promoted tumor growth, while NRG1 knockdown reduced this effect. Conclusion: Our findings suggest that CAF-secreted NRG1 is closely associated with TNBC progression and may represent a potential biomarker and therapeutic target, although further validation is needed to establish causality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.